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Background: Alterations in insulin-like growth factor I (IGF-I) signaling have been
associated with dementia and Alzheimer’s disease (AD). Studies on the association
between IGF-I levels and dementia risk have been inconclusive. We reported earlier that
higher levels of IGF-I receptor stimulating activity are associated with a higher prevalence
and incidence of dementia.
Objective: In the present study, we test the robustness of the association between IGF-I
receptor stimulating activity and dementia by extending the follow-up period to 16 years
and investigate possible effect modification by apolipoprotein E (ApoE).
Methods: At baseline, circulating IGF-I receptor stimulating activity was determined by
the IGF-I kinase receptor activation (KIRA) assay in 1,014 elderly from the Rotterdam
Study. Dementia was assessed from baseline (1997–1999) to follow-up in January 2015.
Associations of IGF-I receptor stimulating activity and incident dementia were assessed
with Cox proportional hazards models.
Results: During 10,752 person-years of follow-up, 174 people developed dementia. In
the extended follow-up we no longer observed a dose-response relationship between
IGF-I receptor stimulating activity and risk of dementia [adjusted odds ratio 1.11; 95%
confidence interval (CI) 0.97–1.28]. Interestingly, we found evidence of an interaction
between ApoE-ε4 and tertiles of IGF-I receptor stimulating activity. IGF-I receptor
stimulating activity in the median and top tertiles was related to increased dementia
incidence in hetero- and homozygotes of the ApoE-ε4 allele, but did not show any
association with dementia risk in people without the ApoE-ε4 allele (adjusted odds
ratio medium vs. low IGF-I receptor stimulating activity in ApoE-ε4 carriers: 1.45;
95% CI 1.00–2.12). These findings suggest a threshold effect in ApoE-ε4 carriers.
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In line with the hypothesis that downregulation of IGF-I signaling is associated with
increased dementia risk, ApoE-ε4 homozygotes without prevalent dementia displayed
lower levels of IGF-I receptor stimulating activity than heterozygotes and non-carriers.
Conclusion: The findings shed new light on the association between IGF-I signaling and
the neuropathology of dementia and ask for replication in other cohorts, using measures
of IGF-I receptor stimulating activity rather than total serum levels as putative markers of
dementia risk.
Keywords: Alzheimer’s disease, dementia, genetic epidemiology, insulin-like growth factor I, KIRA assay,
apolipoprotein E
INTRODUCTION
Insulin-like growth factor I (IGF-I) is a multifunctional peptide
hormone known to modulate multiple cellular processes
including proliferation, differentiation, energy metabolism,
glucose homeostasis, stress resistances and apoptosis.
Downregulation of IGF-I signaling is found in the elderly
and in patients with type 2 diabetes. In contrast, elevated
concentrations of circulating IGF-I have been associated with
an increased risk of prostate, breast (Hankinson et al., 1998;
Renehan et al., 2004; Kaaks, 2008), colorectal (Ma et al., 1999;
Wu et al., 2002; Kaaks, 2008) and lung (Yu et al., 1999) cancer.
IGF-I signaling is also markedly disturbed in the brain of
patients with Alzheimer’s Disease (AD; Frölich et al., 1998,
1999; Moloney et al., 2010) with alterations in both the levels
and phosphorylation state of IGF-I receptor (IGF-IR) as well
as the levels and distribution of IGF-I and IGF-IR mRNA in
the brain (Rivera et al., 2005; Steen et al., 2005). Dysregulation
progresses as the disease advances (Ostrowski et al., 2016). It
remains unclear whether alterations in IGF-I signaling are a
causal factor in the pathogenesis of AD or rather a consequence.
Findings of experimental and observational studies have been
controversial.
In experimental studies, reduced IGF-I signaling has been
linked to increased amyloid β (Aβ) deposition (Carro et al.,
2002; Ashpole et al., 2015), development of phosphorylated tau
(Gasparini et al., 2001, 2002; Cheng et al., 2005), increased
oxidative stress, neuro-inflammation and apoptosis (Bedse et al.,
2015). IGF-I can increase the transport of Aβ carrier proteins
albumin and transthyretin into the brain. Upon systemic
administration, brain levels of albumin and transthyretin
increased and the fraction of Aβ bound to carrier proteins
in the CSF and blood was elevated. Suggesting that IGF-I
reduced brain Aβ load, in part by enhancing its clearance
through carrier proteins such as albumin and transthyretin
(Carro et al., 2002). Systemic administration of IGF-I has also
been shown to lower the toxicity of Aβ in wild type mice
(Aguado-Llera et al., 2005) and restore cognitive function in
mouse models of AD (Carro et al., 2006), supporting the
potential of IGF-I as a therapeutic target in human patients.
Peripheral administration has, however, failed to alter Aβ levels
in trials with transgenic rats, mice and dogs (Lanz et al.,
2008; Sevigny et al., 2008; Parrella et al., 2013; Trueba-Sáiz
et al., 2013). In contrast to the neuroprotective role of IGF-I,
it has also been suggested that the downregulation of IGF-I
signaling attenuates the effects of aging and neurodegeneration.
Suppression of IGF-I signaling has been associated with longevity
in humans (Suh et al., 2008) and has shown to delay the
process of aging and increase lifespan in model organisms (Tatar
et al., 2001; Tazearslan et al., 2011; Milman et al., 2014). In
AD mouse models long term suppression of IGF-IR signaling
has been linked to reduced neuronal loss, greater resistance
to oxidative stress, neuro-inflammation and Aβ aggregation,
and has been associated with prolonged preservation of spatial
memory and a reduction of behavioral deficits, even when plasma
Aβ levels increased (Cohen et al., 2009; Freude et al., 2009;
Gontier et al., 2015; George et al., 2017). Last but not least,
lowering serum IGF-I via a protein restriction diet ameliorated
Alzheimer pathology in transgenic mouse models (Parrella et al.,
2013).
In human observational studies the role of IGF-I signaling
in the risk of AD and dementia remains open to question.
Longitudinal analyses of the cumulative dementia incidence in
3,582 participants of the Framingham Heart Study, spanning
middle and old age, indicated that for those with the lowest levels
of serum IGF-I at baseline dementia risk was increased by 51%
(Westwood et al., 2014). No such relation was found by Green
et al. (2014) examining the prospective association between total
IGF-I, IGF-II, and IGF-I Binding Protein 3 (IGFBP-3) and
cognitive function in 724 males participating in the Caerphilly
Prospective Study. In this study, both total serum IGF-II and
IGFBP-3 were associated with age-related cognitive decline and
cognitive impairment, but previous associations of total serum
IGF-I with cognitive decline and dementia were not replicated.
Correspondingly, a meta-analysis of epidemiological studies on
the association between total serum IGF-I and dementia nullified
the results of previous studies. Five studies suggested that
increased levels of circulating total IGF-I predict a higher risk
of AD, while three studies suggested an inverse association and
two studies reported no significant differences between groups
(Ostrowski et al., 2016). Differences in findings across studies are
speculatively attributed to differences in age of onset and stage
of disease progression, comorbid diabetes, or the differential
influence of IGF-I gene polymorphisms. Although, the majority
of studies report a contribution of alterations in IGF-I signaling
to the prediction of dementia risk independent of apolipoprotein
E (ApoE) genotype (Vargas et al., 2011; Talbot et al., 2012; van
Exel et al., 2014; Lane et al., 2017), Deelen et al. (2011) reported
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an association between the ApoE-ε4 allele and lowered total
serum IGF-I levels in middle-aged women. However, a recent
Mendelian randomization study by Williams et al. (2018) did
not provide any evidence for an association between genetically
predicted variation in total IGF-I or its binding protein IGFBP-3
and risk of AD. These findings decrease the probability that total
serum IGF-I is the relevant determinant of AD and dementia.
As most of the circulating IGF-I measured in serum is bound
to IGF-I binding proteins and therefore biologically inactive,
levels of total IGF-I poorly reflect the actual IGF-I bioactivity.
We therefore applied an IGF-I specific kinase receptor activation
assay (KIRA) to assess IGF-I bioactivity, by measuring IGF-I
receptor stimulating activity (Chen et al., 2003; Brugts et al.,
2010). IGF-I receptor stimulating activity takes into account the
modifying effect of IGF-I binding proteins on the interaction
between IGF-I and the IGF-I receptor and measures the net
effects on IGF-I receptor activation. In a previous study we have
shown that IGF-I bioactivity is positively related to total and
free IGF-I levels obtained by IGF-I immunoassays. Interestingly,
correlations were relatively weak (0.52 for total IGF-I and 0.20 for
free IGF-I respectively), suggesting that the IGF-I KIRA assay
produces new information about IGF-I signaling (Brugts et al.,
2008).
We reported earlier that higher levels of IGF-I receptor
stimulating activity were associated with a higher prevalence and
a higher incidence of dementia (de Bruijn et al., 2014). In light
of the conflicting results of the experimental and human studies,
we aimed to test the long-term robustness of the association
between IGF-I receptor stimulating activity and dementia risk
by extending the follow up period with another 4 years and
investigate possible effect modification by ApoE, the major
genetic driver of AD and dementia risk.
MATERIALS AND METHODS
Setting
This study was embedded within the prospective, population-
based Rotterdam Study, designed to study risk factors and
determinants of chronic diseases in the elderly population. The
Rotterdam Study began in 1990, with an invitation to inhabitants
of 55 years and older residing in Ommoord, a district of
Rotterdam in the Netherlands. Of the 10,215 people invited,
7,983 agreed to participate in the examinations at baseline.
Up until 2015, there have been five follow-up examinations.
Details of the study are described elsewhere (Ikram et al., 2017).
Because IGF-I receptor stimulating activity was measured in
blood samples collected at the second follow-up examination,
between 1997 and 1999, this visit was used as baseline
for the current study. Of the 5,990 participants that were
alive in 1997–1999, 4,797 persons participated in the second
follow-up assessment. IGF-I receptor stimulating activity levels
were measured in blood samples of 1,050 randomly selected
participants due to financial constraints. Five participants
were excluded because their blood samples could not be
correctly matched and 14 participants were excluded because
measurements did not pass prior defined assay acceptance
criteria (inter-assay coefficient of variation <10%). Another
17 participants were excluded because dementia screening was
incomplete. Eventually, 1,014 participants were included in
the analyses. The Rotterdam Study has been approved by the
Medical Ethics Committee of the Erasmus MC (registration
number MEC 02.1015) and by the Dutch Ministry of Health,
Welfare and Sport (Population Screening Act WBO, license
number 1071272-159521-PG). The Rotterdam Study has been
entered into the Netherlands National Trial Register (NTR1)
and into the WHO International Clinical Trials Registry
Platform (ICTRP2) under shared catalog number NTR6831. All
participants provided written informed consent to participate in
the study and to have their information obtained from treating
physicians.
Assessment of IGF-I Receptor Stimulating
Activity
IGF-I receptor stimulating activity levels were measured using
an IGF-I KIRA (intra- and inter-assay coefficients of variation
of 5.2 and 12.2%, respectively; cross-reactivity of 15% for IGF-II;
Chen et al., 2003; Brugts et al., 2008). Details of the assessment
are described previously (de Bruijn et al., 2014).
Assessment of Dementia
Participants were screened for dementia at baseline and
follow-up examinations using a 3-step protocol (Ott et al., 1998).
First, screening was performed using the Mini-Mental State
Examination (MMSE; Folstein et al., 1975) and the Geriatric
Mental Schedule (GMS) organic level (Copeland et al., 1976).
People with a MMSE score lower than 26 or GMS organic
level higher than 0 were subsequently subjected to further
examination and informant interview including the Cambridge
Examination for Mental Disorders in the Elderly (CAMDEX;
Roth et al., 1986). When necessary, participants underwent
further neuropsychological assessment. When information on
neuro-imaging was available, it was used as an aid for decision-
making. For all suspected cases of dementia, the diagnosis
was made by a consensus panel, led by a neurologist. During
follow-up the cohort was under continuous surveillance for
dementia incidence through electronic linkage of the database
of the Rotterdam Study with medical records from general
practitioners and the regional institute for outpatient mental
health care (de Bruijn et al., 2015). The applied criteria for the
diagnosis of dementia and probable AD are in accordance with
the standard criteria for dementia (Diagnostic and Statistical
Manual of Mental Disorders III-revised; American Psychiatric
Association, 1987) and AD (National Institute of Neurological
and Communicative Disorders and Stroke and the AD and
Related Disorders Association; McKhann et al., 2011). The total
cohort was continuously monitored for incidence of dementia
through linkage to the digitized medical records from general
practitioners and the Regional Institute for Outpatient Mental
Health Care. Follow-up for incident dementia is complete until
January 2015.
1www.trialregister.nl
2http://www.who.int/ictrp/network/primary/en/
Frontiers in Aging Neuroscience | www.frontiersin.org 3 February 2019 | Volume 11 | Article 20
Galle et al. IGF-I in Alzheimer’s Disease
Other Measurements
Information on ApoE genotype was obtained using polymerase
chain reaction on coded DNA samples. ApoE-ε4 carrier
status was defined as carrier of one or two ε4 alleles.
Blood pressure was calculated as the average of two
measurements at the right brachial artery using a random-zero
sphygmomanometer. Hypertension was defined as a blood
pressure ≥140/90 mmHg or use of blood pressure lowering
medication, prescribed for the indication of hypertension.
Waist circumference was measured in centimeters. Serum
glucose, total cholesterol, and high-density lipoprotein (HDL)-
cholesterol levels were acquired by an automated enzymatic
procedure (Boehringer Mannheim System). Missing values
in covariates (for ApoE-ε4 carrier status 4.8%, for all other
covariates less than 3.5%) were imputed based on age and
sex.
Statistical Analyses
We examined the association between IGF-I receptor stimulating
activity and incident dementia using Cox proportional hazards
models. IGF-I receptor stimulating activity was entered per
standard deviation (SD) into the models. We also studied IGF-I
receptor stimulating activity in tertiles, using the lowest tertile as
reference. All models were adjusted for age and sex (Model I)
and additionally for hypertension, glucose, waist circumference,
ApoE-ε4 carrier status, total cholesterol, and HDL-cholesterol
(Model II) for being potential confounders. To investigate
possible effect modification by ApoE, the (multiplicative)
interaction between ApoE-ε4 carrier status and IGF-I receptor
stimulating activity on dementia risk was tested using interaction
terms and separate analyses on data stratified on ApoE-
ε4 carrier status were performed. The underlying time-scale
in the Cox proportional hazards models was the follow-up
time, which was defined from time at blood sample collection
(1997–1999) until the end of December 2015. Participants were
censored within this time period when they were diagnosed with
dementia, died, or decided to terminate their participation in the
study. We separately investigated the association between IGF-I
receptor stimulating activity and AD. Analyses were performed
using IBM SPSS statistics version 24.0 (IBM Corp, Armonk,
NY, USA).
TABLE 1 | Baseline characteristics.
Prevalent dementia
N = 30
At risk for incident
dementia N = 984
Age, years 81.54 (8.33) 72.04 (7.1)
Females 70% 55.8%
IGF-IRSA, pmol/L 208.13 (77.59) 179.06 (55.48)
Apolipoprotein E-ε4 carrier status 71.4% 27.4%
Hypertension 82.1% 75.5%
Waist circumference, cm 94.17 (8.33) 93.84 (11.1)
Glucose, mmol/L 6.03 (1.07) 6.01 (1.51)
Total cholesterol, mmol/L 5.52 (1.17) 5.83 (1)
HDL-cholesterol, mmol/L 1.34 (0.46) 1.38 (0.37)
Data are presented as means (standard deviations) or percentages. N, number of people;
IGF-IRSA, insulin-like growth factor I receptor stimulating activity; HDL, high-density
lipoprotein.
RESULTS
Baseline characteristics of the study population are provided in
Table 1. At baseline, 31 participants suffered from prevalent
dementia, of which 23 had AD. During a follow-up of
10,752 person-years (mean follow-up of 11 years, SD 5.2 years),
174 participants developed dementia, of whom 140 were
diagnosed with AD.
In the overall proportional hazard analyses, there was no
statistically significant evidence for a relation between the level
of IGF-I receptor stimulating activity at baseline and risk of
dementia. However, the hazard ratio (HR) per SD increase
in IGF-I receptor stimulating activity [1.11; 95% confidence
interval (CI) 0.97–1.28; see Table 2] was very similar to the
HR reported in our previous analyses (1.15; 95% CI 1.00–1.33)
with shorter follow-up (de Bruijn et al., 2014). A congruent
HR was found for the incidence of AD [HR 1.10 (95% CI
0.95–1.28)].
TABLE 2 | IGF-I receptor stimulating activity and risk of incident dementia.
Dementia Alzheimer’s disease
HR (95% CI) HR (95% CI)
n/N 174/973 n/N 140/973
Model I 1.09 (0.95–1.25) 1.07 (0.92–1.25)
Model II 1.11 (0.97–1.28) 1.10 (0.95–1.28)
Data are presented as hazard ratios (HR) and 95% confidence intervals (CI). N, number
of people at risk for incident dementia; n, number of cases of incident dementia.
IGF IRSA, insulin-like growth factor I receptor stimulating activity. Model I: adjusted for
age and sex. Model II: adjusted for age, sex, hypertension, glucose, waist circumference,
Apolipoprotein E-ε4 status, total cholesterol, and HDL cholesterol.
FIGURE 1 | Cumulative incidence curves of dementia per tertile of
insulin-like growth factor (IGF-I) receptor stimulating activity (IGF-IRSA). Tertile
1 represents the lowest levels of IGF-I receptor stimulating activity, tertile
2 medium levels and tertile 3 the highest levels. ∗ indicates significant at
p < 0.05.
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TABLE 3 | IGF-I receptor stimulating activity stratified by apolipoprotein E (ApoE) group.
Non-carriers
N = 680
ApoE-ε4 heterozygotes
N = 240
ApoE-ε4 homozygotes
N = 17
P for trend
N = 937
IGF-IRSA (pmol/L) 181.92 (58.58) 174.31 (48.24) 151.82 (34.98) F(2) 3.20, p = 0.04
Data are presented as means (standard deviations). N, number of persons; IGF-IRSA, insulin-like growth factor I receptor stimulating activity. Adjusted for age and sex.
TABLE 4 | IGF-I receptor stimulating activity tertile groups and risk of incident dementia.
Dementia Alzheimer’s disease
ApoE–ε4+ ApoE–ε4− ApoE–ε4+ ApoE–ε4−
n/N 65/255 n/N 97/669 n/N 51/255 n/N 78/669
IGF-IRSA groups HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Medium 3.80 (1.90–7.60) 0.97 (0.59–1.60) 3.44 (1.61–7.34) 1.00 (0.57–1.74)
High 2.71 (1.37–5.38) 1.09 (0.67–1.77) 2.38 (1.12–5.08) 1.01 (0.86–1.75)
Medium vs. High 1.40 (0.79–2.48) 0.89 (0.54–1.46) 1.44 (0.75–2.76) 0.99 (0.57–1.73)
Data are presented as hazard ratios (HR) and 95% confidence intervals (CI). N, number of people at risk for incident dementia. n, number of cases of incident dementia. IGF-IRSA,
insulin-like growth factor I receptor stimulating activity divided in tertile groups. The lowest tertile group is used as reference. Adjusted for age, sex, hypertension, glucose, waist
circumference, total cholesterol, and HDL cholesterol.
Figure 1 shows the cumulative incidence curves of dementia
per tertile of IGF-I receptor stimulating activity. Proportional
hazard analyses of dementia incidence revealed that those in the
lowest tertile of IGF-I receptor stimulating activity at baseline
had the lowest risk of dementia [HR moderate vs. low: 1.45 (95%
CI 1.00–2.12); HR high vs. low 1.40 (95% CI 0.96–2.04)], while
there was no difference in risk of dementia between the medium
and highest tertiles (Figure 1).
IGF-I Receptor Activity and ApoE-ε4
At baseline there was a statistically significant difference in IGF-I
receptor stimulating activity between ApoE-ε4 genotype groups
without dementia (non-carrier, heterozygote and homozygote),
after adjustment for age and sex (p = 0.04; see Table 3). The
levels of IGF-I receptor stimulating activity were significantly
lower in homozygotes for ApoE-ε4 than in people with no copies
of the ApoE-ε4 allele (p = 0.04). There were no statistically
significant differences in level of IGF-I receptor stimulating
activity between non-carriers and ApoE-ε4 heterozygotes or
ApoE-ε4 heterozygotes and homozygotes.
When testing for effect modification, significant evidence for
a multiplicative interaction between IGF-I receptor stimulating
activity and ApoE-ε4 carrier status was observed (χ2(2) = 10.85,
p = 0.004). In those without the ApoE-ε4 variant, the level of
IGF-I receptor stimulating activity was not associated with the
risk of dementia (medium vs. low: HR 0.97 (95% CI 0.59–1.60);
high vs. low: HR 1.09 (95% CI 0.67–1.77); χ2(2) = 0.24, p = 0.89).
For those with one or more copies of the ApoE-ε4 allele, level
of IGF-I receptor stimulating activity was positively associated
with dementia risk. Dementia risk was significantly increased
in people with one or more copies of the ApoE-ε4 allele and
IGF-1 receptor stimulating activity in the median and top tertiles
compared to those with IGF-I receptor stimulating activity in the
bottom tertile [medium vs. low: HR 3.80 (95%CI 1.90–7.60); high
vs. low: HR 2.71 (95% CI 1.37–5.38)].
Similar results were found for the incidence of AD (Table 4).
Figures 2A,B show the cumulative incidence of dementia per
tertile group of IGF-I receptor stimulating activity, stratified by
ApoE-ε4 genotype.
DISCUSSION
In the extended follow-up period of 16 years, our study did
not find evidence for a long-term dose response association
between circulating IGF-I receptor stimulating activity at
baseline and the future risk of dementia. Interestingly, we
found evidence of an interaction between ApoE-ε4 and IGF-I
receptor stimulating activity. In those hetero- and homozygous
for the ApoE-ε4 allele, dementia risk was increased in persons
with medium and high levels of IGF-I receptor stimulating
activity at baseline, compared to those with low IGF-I receptor
stimulating activity at baseline. However, no relation between
IGF-I receptor stimulating activity and dementia risk was
observed in non-carriers of the ApoE-ε4 allele. This suggests
that, in ApoE-ε4 carriers, there is a certain threshold above
which IGF-I receptor stimulating activity becomes associated
with dementia at long-term follow up. In addition, in individuals
without dementia, IGF-I receptor stimulating activity was lower
in homozygote carriers of ApoE-ε4 than in people with other
ApoE genotypes.
To our knowledge the Rotterdam Study is still the only
study that has investigated the role of circulating IGF-I receptor
stimulating activity in relation to dementia. As circulating IGF-I
receptor stimulating activity is only modestly correlated to total
serum IGF-I and IGF-I/IGFBP-3 ratio (Brugts et al., 2008),
comparison to other studies on serum total IGF-I, measured by
immunoassays, and dementia risk, described by Ostrowski et al.
(2016) is difficult.
We found a modifying effect of ApoE-ε4 on circulating IGF-I
receptor stimulating activity at baseline and an interaction on
the relation between IGF-I receptor stimulating activity and the
risk of dementia. The observed interaction between circulating
IGF-I receptor stimulating activity and ApoE isoforms in our
study could reflect opposing influences on shared pathways
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FIGURE 2 | (A) Cumulative incidence curves of dementia per tertile of IGF-I receptor stimulating activity (IGF-IRSA), for persons without apolipoprotein E ε4 allele
(ApoE-ε4). Tertile 1 represents the lowest levels of IGF-I receptor stimulating activity, tertile 2 medium levels and tertile 3 the highest levels. (B) Cumulative incidence
curves of dementia per tertile of IGF-I receptor stimulating activity (IGF-IRSA), for hetero- and homozygotes of the ApoE-ε4 allele. Tertile 1 represents the lowest levels
of IGF-I receptor stimulating activity, tertile 2 medium levels and tertile 3 the highest levels. ∗ Indicates significant at p < 0.05.
involved in Alzheimer pathology. Both ApoE and IGF-I are
involved in the regulation of AD biomarkers: IGF-I is an
important mediator in the clearance and regulation of Aβ
in the brain, enhances survival of neurons exposed to Aβ
and inhibits tau phosphorylation (Doré et al., 1997; Carro
et al., 2002, 2006; Cheng et al., 2005; Engel et al., 2006;
Moloney et al., 2010; Talbot et al., 2012). The ApoE-ε4 allele,
on the other hand, is associated with decreased Aβ1–42 and
higher tau and p-tau in the CSF and increased cerebral
amyloid deposition across the AD spectrum (Tapiola et al.,
2000; Morris et al., 2010; Leoni, 2011; Risacher and Saykin,
2013; Wildsmith et al., 2013; Kanekiyo et al., 2014). In mice
expressing human ApoE-ε4, increased tau phosphorylation has
been demonstrated (Tesseur et al., 2000). ApoE-ε4 and IGF-I
also have an opposing influence on NMDA receptor signaling.
The NR2B subunit of the NMDA receptor, in particular, is
suggested to be of specific importance for spatial learning
and long-term potentiation, impaired in AD (Sonntag et al.,
2000; Le Grevès et al., 2005; Reiman et al., 2009). The ApoE-
ε4 genotype is associated with decreased NR2B NMDA receptor
subunit levels and enhances age-related decline in cognitive
function by down-regulating signaling in mice (Liu et al.,
2015). In contrast, IGF-I positively affects the NMDA receptor
pathway by increasing the NR2B subunit mRNA transcript of the
hippocampal NMDA receptor in rats (Sonntag et al., 2000; Le
Grevès et al., 2005). The observed association between elevated
levels of IGF-I receptor stimulating activity and increased risk
of dementia in ApoE-ε4 carriers might thus be a reflection of a
compensatory response to neuropathological changes associated
with the ApoE-ε4 genotype and a preclinical loss of sensitivity of
the IGF-I receptor.
The strengths of our study are its prospective, population-
based design, the long follow-up period, and the use of a
direct measure of circulating IGF-I receptor stimulating activity.
However, there are also some limitations. First, IGF-I receptor
stimulating activity was only measured in peripheral blood
samples. Even though circulating IGF-I crosses the blood-
brain barrier, we could not assess the extent to which our
measurements of circulating IGF-I receptor stimulating activity
are related to actual IGF-I receptor stimulating activity in the
brain (Reinhardt and Bondy, 1994). In addition, IGF-I has
important autocrine and paracrine actions at the tissue level.
However, IGF-I measured by the KIRA assay may not necessarily
reflect IGF-I bioactivity at the local tissue level (Chen et al.,
2003). Second, no total serum IGF-I levels were measured in
our study, therefore we were unable to compare the relationship
of IGF-I receptor stimulating activity and total IGF-I with
dementia and to show that measuring IGF-I bioactivity with
the IGF-I KIRA assay provides other insights about the role of
IGF-I in dementia than the measurement of total IGF-I. Third,
IGF-I receptor stimulating activity was assessed at the second
follow-up visit of the Rotterdam Study, which might have led
to survival effects in the study population which was included at
baseline.
In conclusion, our current study sheds new light on the
association between IGF-I signaling and the neuropathology
of dementia, suggesting a threshold effect of IGF-I receptor
stimulating activity moderated by ApoE genotype, since only
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for those with one or more copies of the ApoE-ε4 allele
and in the lowest tertile of IGF-I receptor stimulating activity
the risk of future dementia is decreased. Our study suggests
that the ApoE-ε4 genotype modifies the relationship between
IGF-I receptor stimulating activity and dementia and elevated
IGF-I receptor stimulating activity levels mark a compensatory
response to neuropathological changes associated with the
ApoE-ε4 genotype. In line with the hypothesis that low IGF-I
activity increases the risk of dementia, we found the ApoE-
ε4 homozygotes, with a lifetime risk of AD of 80% (van der
Lee et al., 2018), have the lowest IGF-I levels. This provides a
genetic benchmark for the hypothesis that low IGF-I receptor
stimulating activity is associated with an increased risk of AD.
However, our findings require replication in other cohorts,
reusing measures of IGF-I receptor stimulating activity rather
than total IGF-I serum levels as putative predictors of dementia
risk.
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